Biomarkers for atherosclerotic cardiovascular diseases
An atherosclerosis, biomarker technology, applied in the determination/examination of microorganisms, biochemical equipment and methods, DNA/RNA fragments, etc., can solve the problem of lack of metagenomics to characterize large research cohorts and hinder research.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment approach
[0024] An embodiment of the third broad aspect of the present disclosure provides a method of predicting the risk of atherosclerotic cardiovascular disease or a related condition thereof. According to an embodiment of the present invention, the method includes: (1) determining the relative abundance of the above-mentioned biomarkers in the sample of the test subject; and (2) predicting atherosclerosis based on the relative abundance of the above-mentioned biomarkers risk of sclerotic cardiovascular disease or its related conditions. The above method can effectively predict the risk of atherosclerotic cardiovascular disease or its related conditions. The reliability of the prediction results is high.
[0025] According to an embodiment of the present disclosure, wherein the relative abundance of the biomarkers is obtained by sequencing.
[0026] According to an embodiment of the present disclosure, step (2) includes comparing the relative abundance of the biomarker with a pre...
Embodiment
[0035] Identification of 3 biomarkers to assess ACVD risk
[0036] Sample Collection
[0037] Samples from 405 subjects, including 218 individuals with ACVD and 187 control subjects, were collected at the Medical Research Center of Guangdong General Hospital. Individuals with ACVD exhibit clinical manifestations of stable angina, unstable angina, or acute myocardial infarction (AMI) (Table 1). ACVD diagnosis was confirmed by coronary angiography, and individuals with ≥50% stenosis in single or multiple vessels were enrolled. All patients were of Chinese Han nationality, unrelated, aged between 40 and 80 years old. Exclusion criteria included persistent infectious disease, cancer, renal or hepatic failure, peripheral neuropathy, stroke, and antibiotic use within one month of sample collection. At the time of physical examination, all enrolled healthy control individuals were free of clinically significant symptoms of ACVD. Demographic data and cardiovascular risk factors w...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com